Literature DB >> 21840716

Clonal Rett Syndrome cell lines to test compounds for activation of wild-type MeCP2 expression.

Dongbo Yu1, Fuminori Sakurai, David R Corey.   

Abstract

Rett Syndrome is an X-linked progressive neurological disorder caused by inactivation of one allele of the MECP2 gene. There are no curative treatments, and activation of wild-type MECP2 expression is one strategy for stabilizing or reversing the disease. We isolated fibroblast clones that express exclusively either the wild-type or a 32-bp-deletion mutant form of MECP2. We developed a sensitive assay for measuring wild-type MECP2 mRNA levels and tested small molecule epigenetic activators for their ability to activate gene expression. Although our pilot screen did not identify activators of MECP2 expression, it established the value of using clonal cells and defined challenges that must be overcome.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21840716      PMCID: PMC3159815          DOI: 10.1016/j.bmcl.2011.07.053

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  29 in total

1.  Rett syndrome: epidemiology and geographical variability.

Authors:  B Hagberg; G Hagberg
Journal:  Eur Child Adolesc Psychiatry       Date:  1997       Impact factor: 4.785

2.  Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice.

Authors:  R Z Chen; S Akbarian; M Tudor; R Jaenisch
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

3.  A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome.

Authors:  J Guy; B Hendrich; M Holmes; J E Martin; A Bird
Journal:  Nat Genet       Date:  2001-03       Impact factor: 38.330

4.  The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression.

Authors:  Qiang Chang; Gargi Khare; Vardhan Dani; Sacha Nelson; Rudolf Jaenisch
Journal:  Neuron       Date:  2006-02-02       Impact factor: 17.173

Review 5.  DNA methyltransferase inhibitors: old and new drugs for an epigenetic cancer therapy.

Authors:  Bodo Brueckner; Frank Lyko
Journal:  Trends Pharmacol Sci       Date:  2004-11       Impact factor: 14.819

6.  Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology.

Authors:  Nurit Ballas; Daniel T Lioy; Christopher Grunseich; Gail Mandel
Journal:  Nat Neurosci       Date:  2009-02-22       Impact factor: 24.884

Review 7.  Therapeutic application of histone deacetylase inhibitors for central nervous system disorders.

Authors:  Aleksey G Kazantsev; Leslie M Thompson
Journal:  Nat Rev Drug Discov       Date:  2008-10       Impact factor: 84.694

8.  Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations.

Authors:  Jennifer L Larimore; Christopher A Chapleau; Shinichi Kudo; Anne Theibert; Alan K Percy; Lucas Pozzo-Miller
Journal:  Neurobiol Dis       Date:  2009-01-03       Impact factor: 5.996

9.  Gene expression patterns vary in clonal cell cultures from Rett syndrome females with eight different MECP2 mutations.

Authors:  Jeff Traynor; Priyanka Agarwal; Laura Lazzeroni; Uta Francke
Journal:  BMC Med Genet       Date:  2002-11-05       Impact factor: 2.103

10.  MeCP2, a key contributor to neurological disease, activates and represses transcription.

Authors:  Maria Chahrour; Sung Yun Jung; Chad Shaw; Xiaobo Zhou; Stephen T C Wong; Jun Qin; Huda Y Zoghbi
Journal:  Science       Date:  2008-05-30       Impact factor: 47.728

View more
  7 in total

Review 1.  Rett syndrome and MeCP2.

Authors:  Vichithra R B Liyanage; Mojgan Rastegar
Journal:  Neuromolecular Med       Date:  2014-03-11       Impact factor: 3.843

2.  Genetic and pharmacological reactivation of the mammalian inactive X chromosome.

Authors:  Sanchita Bhatnagar; Xiaochun Zhu; Jianhong Ou; Ling Lin; Lynn Chamberlain; Lihua J Zhu; Narendra Wajapeyee; Michael R Green
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-18       Impact factor: 11.205

3.  Rett syndrome-causing mutations compromise MeCP2-mediated liquid-liquid phase separation of chromatin.

Authors:  Liang Wang; Mingli Hu; Mei-Qing Zuo; Jicheng Zhao; Di Wu; Li Huang; Yongxin Wen; Yunfan Li; Ping Chen; Xinhua Bao; Meng-Qiu Dong; Guohong Li; Pilong Li
Journal:  Cell Res       Date:  2020-02-28       Impact factor: 25.617

4.  Elucidation of the pathogenic mechanism and potential treatment strategy for a female patient with spastic paraplegia derived from a single-nucleotide deletion in PLP1.

Authors:  Keiko Yamamoto-Shimojima; Taichi Imaizumi; Yusuke Aoki; Ken Inoue; Tadashi Kaname; Yusuke Okuno; Hideki Muramatsu; Kohji Kato; Toshiyuki Yamamoto
Journal:  J Hum Genet       Date:  2019-04-19       Impact factor: 3.172

5.  Inhibitors of Histone Deacetylases Are Weak Activators of the FMR1 Gene in Fragile X Syndrome Cell Lines.

Authors:  Alexander A Dolskiy; Vladimir O Pustylnyak; Andrey A Yarushkin; Natalya A Lemskaya; Dmitry V Yudkin
Journal:  Biomed Res Int       Date:  2017-10-25       Impact factor: 3.411

6.  Decitabine alters the expression of Mecp2 isoforms via dynamic DNA methylation at the Mecp2 regulatory elements in neural stem cells.

Authors:  Vichithra R B Liyanage; Robby M Zachariah; Mojgan Rastegar
Journal:  Mol Autism       Date:  2013-11-15       Impact factor: 7.509

Review 7.  Regulation of mammalian transcription and splicing by Nuclear RNAi.

Authors:  Roya Kalantari; Cheng-Ming Chiang; David R Corey
Journal:  Nucleic Acids Res       Date:  2015-11-26       Impact factor: 16.971

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.